scholarly journals Immune Profile of Mucosal-Associated Invariant T Cells in Chronic Viral Hepatitis: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 19 (8) ◽  
Author(s):  
Qinling Liu ◽  
Feng Zhu ◽  
Yujing Shi ◽  
Dazhi Zhang
2021 ◽  
Vol 53 (1) ◽  
pp. 1227-1242
Author(s):  
Amir Vahedian-Azimi ◽  
Sajad Shojaie ◽  
Maciej Banach ◽  
Farshad Heidari ◽  
Arrigo F. G. Cicero ◽  
...  

2016 ◽  
Vol 16 (12) ◽  
pp. 1409-1422 ◽  
Author(s):  
Kali Zhou ◽  
Thomas Fitzpatrick ◽  
Nick Walsh ◽  
Ji Young Kim ◽  
Roger Chou ◽  
...  

2013 ◽  
Vol 14 (18) ◽  
pp. 2533-2544 ◽  
Author(s):  
Ferdinando Fusco ◽  
Gianluca D'Anzeo ◽  
Andrea Rossi ◽  
Carmine Sciorio ◽  
Antonio Riccardo Buonomo ◽  
...  

2016 ◽  
Vol 34 (4) ◽  
pp. 293-302 ◽  
Author(s):  
Hubert E. Blum

Between 1963 and 1989, 5 hepatotropic viruses have been discovered that are the major causes of viral hepatitides worldwide: hepatitis A virus, hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis delta virus and hepatitis E virus. Their epidemiology and pathogenesis have been studied in great detail. Furthermore, the structure and genetic organization of their DNA or RNA genome including the viral life cycle have been elucidated and have been successfully translated into important clinical applications, such as the specific diagnosis, therapy and prevention of the associated liver diseases, including liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic viral hepatitis A-E shows distinct geographic differences. The global burden of disease (prevalence, incidence, death, disability-adjusted life years) has been analyzed in seminal studies that show that the worldwide prevalence of hepatitis A-E has significantly decreased between 1990 and 2013. During the same time, the incidence of HBV-related liver cirrhosis and HCC, respectively, also decreased or increased slightly, the incidence of the HCV-related liver cirrhosis remained stable and the incidence of HCV-related HCC showed a major increase. During the coming years, we expect to improve our ability to prevent and effectively treat viral hepatitis A-E, resulting in the control of these global infections and the elimination of their associated morbidities and mortalities.


Sign in / Sign up

Export Citation Format

Share Document